Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Yuli Wang

Physician Assistant Los Angeles, CA Physician Assistant

NPI 1801242581 CMS profile 10712361

1414 S Grand Ave, Suite 200, Los Angeles, CA 90015

Open in the dashboard

General payments

$15,276

599 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yuli Wang of Los Angeles, CA is reported in the CMS Open Payments database as having received $15,276 across 599 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,851 159
2024 General $3,963 148
2023 General $3,893 151
2022 General $2,204 87
2021 General $1,365 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yuli Wang
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Yuli Wang were reported at $3,851. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Yuli Wang Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,365 $132 $37–$438 $132
2022 $2,204 $155 $48–$522 $149
2023 $3,893 $167 $52–$557 $160
2024 $3,963 $178 $55–$600 $164
2025 $3,851 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,758 129 payments
  2. Incyte Corporation $1,538 52 payments
  3. Genzyme Corporation $1,529 41 payments
  4. Regeneron Healthcare Solutions, Inc. $1,416 39 payments
  5. Sun Pharmaceutical Industries Inc. $1,253 58 payments
  6. E.R. Squibb & Sons, L.L.C. $1,058 44 payments
  7. Galderma Laboratories, L.P. $626 20 payments
  8. LEO Pharma Inc. $613 32 payments
  9. STRATA Skin Sciences, Inc. $519 14 payments
  10. UCB, Inc. $403 12 payments
  11. Other $3,561 158 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,924 594 payments
  2. Education $352 5 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,555 42 payments
  2. OPZELURA $1,377 50 payments
  3. SKYRIZI Immunology $1,310 60 payments
  4. DUPIXENT Inflammation And Immunology $1,248 34 payments
  5. SOTYKTU $1,020 41 payments
  6. RINVOQ $729 39 payments
  7. SKYRIZI Immunology $575 24 payments
  8. ADBRY $537 29 payments
  9. XTRAC $519 14 payments
  10. ILUMYA $500 19 payments
  11. Other $6,718 302 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

299

Median for Physician Assistant: 241

Drug cost

$83,935

Median for Physician Assistant: $4,110

Branded share of claims

6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 18 $66,725
Tacrolimus Generic 27 $9,959
Betamethasone Dipropionate Generic 39 $2,017
Clobetasol Propionate Generic 39 $1,863
Ivermectin Generic 15 $1,512
Ketoconazole Generic 73 $849
Clindamycin Phosphate Generic 14 $573
Triamcinolone Acetonide Generic 29 $203
Mupirocin Generic 31 $185
Minoxidil Generic 14 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$885 18 —
SKYRIZI
$460 — —
RINVOQ
$441 — —
SOTYKTU
$439 — —
ADBRY
$138 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

599 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record